458 related articles for article (PubMed ID: 10428929)
1. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.
Delaney WE; Miller TG; Isom HC
Antimicrob Agents Chemother; 1999 Aug; 43(8):2017-26. PubMed ID: 10428929
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus.
Delaney WE; Isom HC
Hepatology; 1998 Oct; 28(4):1134-46. PubMed ID: 9755254
[TBL] [Abstract][Full Text] [Related]
3. Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatment.
Abdelhamed AM; Kelley CM; Miller TG; Furman PA; Isom HC
J Virol; 2002 Aug; 76(16):8148-60. PubMed ID: 12134020
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma.
Parvez MK; Sehgal D; Sarin SK; Basir SF; Jameel S
World J Gastroenterol; 2006 May; 12(19):3006-14. PubMed ID: 16718779
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro.
Starkey JL; Chiari EF; Isom HC
J Gen Virol; 2009 Jan; 90(Pt 1):115-26. PubMed ID: 19088280
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity of 5'-O-carbonate-2',3'-dideoxy-3'-thiacytidine prodrugs against hepatitis B virus in HepG2 2.2.15 cells.
Gagey D; Ravetti S; Castro EF; Gualdesi MS; Briñon MC; Campos RH; Cavallaro LV
Int J Antimicrob Agents; 2010 Dec; 36(6):566-9. PubMed ID: 20947311
[TBL] [Abstract][Full Text] [Related]
7. Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay.
Abdelhamed AM; Kelley CM; Miller TG; Furman PA; Cable EE; Isom HC
Antimicrob Agents Chemother; 2003 Jan; 47(1):324-36. PubMed ID: 12499209
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.
Melegari M; Scaglioni PP; Wands JR
Hepatology; 1998 Feb; 27(2):628-33. PubMed ID: 9462667
[TBL] [Abstract][Full Text] [Related]
9. In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication.
Heipertz RA; Miller TG; Kelley CM; Delaney WE; Locarnini SA; Isom HC
J Virol; 2007 Apr; 81(7):3068-76. PubMed ID: 17215289
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus.
Moraleda G; Saputelli J; Aldrich CE; Averett D; Condreay L; Mason WS
J Virol; 1997 Dec; 71(12):9392-9. PubMed ID: 9371599
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine.
King RW; Ladner SK; Miller TJ; Zaifert K; Perni RB; Conway SC; Otto MJ
Antimicrob Agents Chemother; 1998 Dec; 42(12):3179-86. PubMed ID: 9835512
[TBL] [Abstract][Full Text] [Related]
12. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.
Delaney WE; Edwards R; Colledge D; Shaw T; Torresi J; Miller TG; Isom HC; Bock CT; Manns MP; Trautwein C; Locarnini S
Antimicrob Agents Chemother; 2001 Jun; 45(6):1705-13. PubMed ID: 11353615
[TBL] [Abstract][Full Text] [Related]
13. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.
Levine S; Hernandez D; Yamanaka G; Zhang S; Rose R; Weinheimer S; Colonno RJ
Antimicrob Agents Chemother; 2002 Aug; 46(8):2525-32. PubMed ID: 12121928
[TBL] [Abstract][Full Text] [Related]
14. Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation.
Luo J; Luckenbaugh L; Hu H; Yan Z; Gao L; Hu J
mBio; 2020 Feb; 11(1):. PubMed ID: 32071277
[TBL] [Abstract][Full Text] [Related]
15. Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector.
Lucifora J; Durantel D; Belloni L; Barraud L; Villet S; Vincent IE; Margeridon-Thermet S; Hantz O; Kay A; Levrero M; Zoulim F
J Gen Virol; 2008 Aug; 89(Pt 8):1819-1828. PubMed ID: 18632952
[TBL] [Abstract][Full Text] [Related]
16. T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.
Qu B; Ni Y; Lempp FA; Vondran FWR; Urban S
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232183
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
18. Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment.
Shi H; Lu L; Zhang NP; Zhang SC; Shen XZ
World J Gastroenterol; 2012 Jul; 18(27):3617-22. PubMed ID: 22826629
[TBL] [Abstract][Full Text] [Related]
19. Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line.
He W; Li LX; Liao QJ; Liu CL; Chen XL
World J Gastroenterol; 2011 Mar; 17(11):1507-14. PubMed ID: 21472112
[TBL] [Abstract][Full Text] [Related]
20. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
Sheraz M; Cheng J; Tang L; Chang J; Guo JT
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
